CalciMedica (CALC) grants director 10,000 stock options at $0.61

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reported that director Frederic Guerard received a grant of 10,000 Director Stock Options on 2026-08-19. Each option allows purchase of one share of common stock at an exercise price of $0.6131 per share and expires on 2036-08-18. According to the vesting terms, 1/12th of the options vest in equal monthly installments over one year following the grant date, and the options will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Guerard holds 10,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Guerard Frederic

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 10,000 shares (Direct)

Footnotes (1)

1. F1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

Key Figures

Director Stock Options Granted: 10,000 options Exercise price: $0.6131 per share Expiration date: 2036-08-18 +3 more

6 metrics

Director Stock Options Granted 10,000 options Grant to director Frederic Guerard on 2026-08-19

Exercise price $0.6131 per share Exercise price of Director Stock Option grant

Expiration date 2036-08-18 Option term end date for the Director Stock Options

Underlying shares 10,000 shares Common Stock underlying the Director Stock Options

Post-transaction derivative holdings 10,000 options Total derivative securities held directly after the grant

Vesting rate 1/12th monthly over one year Vesting schedule for the option grant

Key Terms

Director Stock Option, vesting, annual meeting of stockholders

3 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

vesting financial

"1/12th of the shares subject to the option vest in equal monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"fully vested on the date of the 2027 annual meeting of stockholders"

FAQ

What insider transaction did CALC report for Frederic Guerard?

CalciMedica, Inc. reported that director Frederic Guerard received a grant of 10,000 Director Stock Options on 2026-08-19, each for one share of common stock at an exercise price of $0.6131 per share, expiring on 2036-08-18.

What is the vesting schedule for Frederic Guerard’s new CALC stock options?

The filing states that 1/12th of the shares subject to the option vest in equal monthly installments over a one-year period after the grant date, and the option will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders.

What is the exercise price and term of the new CALC options granted to Frederic Guerard?

The options have an exercise price of $0.6131 per share and an expiration date of 2036-08-18, giving Frederic Guerard the right to buy CalciMedica common stock at that price until that date, subject to vesting.

How many derivative securities does Frederic Guerard hold in CALC after this transaction?

After the reported grant, Frederic Guerard’s total reported derivative holdings are 10,000 Director Stock Options, held directly, as indicated by the total shares following the transaction field.

Was the CALC option grant to Frederic Guerard made under a Rule 10b5-1 plan?

The document-level Rule 10b5-1 checkbox is unchecked (false), and the footnote does not reference any Rule 10b5-1 trading plan, so the filing does not identify this grant as made under such a plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 06:46 PM Accepted by SEC EDGAR 08/21/2026 - 06:45 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guerard Frederic

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, #202

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.6131	08/19/2026		A		10,000		(1)	08/18/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

	/s/ John Dunn, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)